Konrad Aden is interested in the molecular pathophysiology of inflammatory bowel disease(IBD). IBD is characterized by fundamental disturbance of the amino acid metabolism, but the underlying molecular cause remains elusive. The aim of his research is to decipher the cause and consequences of disrupted amino acid immunometabolism and to translate key molecular findings into novel diagnostic and therapeutic approaches in the management of IBD.